Mendus data presented at EHA substantiate the potential of vididencel to induce functional, clinically relevant immune responses in AML
Keep reading
ALISON trial data presented at ESMO Gynaecological Cancers demonstrate tumor-directed immune responses in the majority of patients treated with vididencel
